Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desloratadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 14/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | DRD2 | P14416 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
| ▸ | DRD4 | P21917 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desloratadine SCHEMBL4574215 | 1.00 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5374223 | 0.99 | HRH1 (0.95) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL29390260 | 0.99 | HRH1 (1.00) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL4425 | 0.99 | HRH1 (1.00) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL29371361 | 0.99 | HRH1 (1.00) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5198706 | 0.97 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5200429 | 0.97 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5378852 | 0.96 | HRH1 (0.95) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL3558046 | 0.93 | HRH1 (0.89) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL28307951 | 0.93 | HRH1 (0.89) | HRH1MEN1LMNAADRB2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | claimed |
| EP-4053116-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD Bioscience Inc. (KR) | 2022-09-07 | — | — | EP | claimed |
| CN-114616229-A | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2022-06-10 | — | — | CN | claimed |
| WO-2021086133-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | (주)제이디바이오사이언스 | 2021-05-06 | — | — | WO | claimed |
| CN-114616229-B | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4053116-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD Bioscience Inc. (KR) | 2022-09-07 | — | — | EP | disclosed |
| CN-114616229-A | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021086133-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | (주)제이디바이오사이언스 | 2021-05-06 | — | — | WO | disclosed |
| EP-1817307-A2 | NEW PSEUDOPOLYMORPH OF DESLORATADINE FORMED WITH CARBON DIOXIDE | EGIS GYOGYSZERGYAR RT. (HU) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006003479-A2 | NEW PSEUDOPOLYMORPH OF DESLORATADINE FORMED WITH CARBON DIOXIDE | EGIS Gyógyszergyár Rt. (HU) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TPH1, SLC6A4, TPH2 | HRH1 1035/4885MEN1 726/4885LMNA 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.